US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Barclays ETN+ Select MLP ETNs

28.70

+0.42001.49%

Post-market: 28.700.00000.00%16:05 EDT

Volume:10.91K

Turnover:312.46K

Market Cap:501.89M

PE:- -

High:28.73

Open:28.40

Low:28.40

Close:28.28

Loading ...

Overview Company News Filings

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

US-China tariff tussle gives India chance to rewire global tech manufacturing

ByVishal Mathur

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATMP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","market":"US","secType":"STK","nameCN":"Barclays ETN+ Select MLP ETNs","latestPrice":28.7,"timestamp":1746216000000,"preClose":28.28,"halted":0,"volume":10905,"hourTrading":{"tag":"盘后","latestPrice":28.7,"preClose":28.7,"latestTime":"16:05 EDT","volume":3,"amount":86.1,"timestamp":1746216309952},"delay":0,"floatShares":17487506,"shares":17487506,"eps":0,"marketStatus":"Post-Mkt","change":0.42,"latestTime":"05-02 16:31:06 EDT","open":28.3985,"high":28.73,"low":28.3985,"amount":312462.8886,"amplitude":0.011722,"askPrice":43.02,"askSize":200,"bidPrice":14.34,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746230400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":28.28,"sharesOutstanding":17487506,"nav":28.3264,"aum":495421044.98,"dividendRate":0.046829,"bidAskSpread":0.001977,"postHourTrading":{"tag":"盘后","latestPrice":28.7,"preClose":28.7,"latestTime":"16:05 EDT","volume":3,"amount":86.1,"timestamp":1746216309952},"volumeRatio":0.443769,"impliedVol":0.067,"impliedVolPercentile":0.152},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATMP\",,,,,undefined,":{"symbol":"ATMP","floatShares":17487506,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.443769,"shares":17487506,"dividePrice":1.344,"high":28.73,"amplitude":0.011722,"preClose":28.28,"low":28.3985,"week52Low":23.77,"pbRate":"--","week52High":32.09,"institutionHeld":0,"latestPrice":28.7,"eps":0,"divideRate":0.046829,"volume":10905,"delay":0,"ttmEps":0,"open":28.3985,"prevYearClose":28.28,"prevWeekClose":29.19,"prevMonthClose":28.46,"prevQuarterClose":30.66,"fiveDayClose":29.19,"twentyDayClose":29.88,"sixtyDayClose":31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATMP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532848245","title":"Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2532848245","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532848245?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"Data will be featured at the ASGCT 28th Annual Meeting. BRISBANE, Calif., May 02, 2025  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 , a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy  in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies  impact the therapy’s efficacy, safety, and redosing potential.Presentation Title: Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy. Date and Time: Thursday, May 15 from 2:15–2:30 PM CT, during the “Immunogenicity/NAb Titers” oral session at ASGCT 2025. Given the promising Phase 1 resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-present-data-clinical-120000290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATMP","BK4007","PCRX"],"gpt_icon":1},{"id":"2530401340","title":"Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee","url":"https://stock-news.laohu8.com/highlight/detail?id=2530401340","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530401340?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"-- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease --. -- Study Findings Presented at 2025 OARSI World Congress--. BRISBANE, Calif., April 28, 2025  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its locally administered gene therapy candidate, PCRX-201 , provided sustained improvements in knee pain, stiffness, and function for up to two years following a single local administration in patients with mild, moderate, as well as severe osteoarthritis of the knee. The data was presented during a poster session at the 2025 Osteoarthritis Research Society International  World Congress in Incheon, South Korea, on Friday, April 25, and Saturday, April 26.The open-label, phase 1 trial investigated the efficacy of PCRX-201 administe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-announces-two-efficacy-120000555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","BK4007","ATMP"],"gpt_icon":0},{"id":"2529557038","title":"Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee","url":"https://stock-news.laohu8.com/highlight/detail?id=2529557038","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529557038?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:01","pubTimestamp":1745352060,"startTime":"0","endTime":"0","summary":"-- Poster to be presented at OARSI World Congress on Osteoarthritis --. BRISBANE, Calif., April 22, 2025  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 . The data is being presented at the 2025 Osteoarthritis Research Society International  World Congress in Incheon, South Korea, April 24-27.Presentation Title: Improvements in Pain, Stiffness, and Function After a Single Intraarticular Injection of Gene Therapy PCRX-201 for Knee Arthritis Osteoarthritis: A Subgroup Analysis by Structural Severity. Presented By: Ali Mobasheri, Professor of Musculoskeletal Biology at the University of Oulu in Oulu, Finland; Chief Researcher and International Adviser in the State Research Institute Centre for Innovative Medicine in Vilnius, Lithuania. PCRX-201  featur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-present-104-week-200100290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PCRX","ATMP","BK4007"],"gpt_icon":0},{"id":"2527906645","title":"US-China tariff tussle gives India chance to rewire global tech manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527906645","media":"ByVishal Mathur","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527906645?lang=en_us&edition=fundamental","pubTime":"2025-04-14 13:09","pubTimestamp":1744607340,"startTime":"0","endTime":"0","summary":"There may be little scope of understanding any long-term direction, considering Trump’s dynamic propensity  to move goalposts. The administration’s focus, as US commerce secretary Howard Lutnick said in a media statement, points to an urgent “need to have these things made in America.” . The narrative and specifics may again change, in the coming days. Nevertheless, a few questions do need answering — quite what does this mean for the country’s trade with China, any possible realignment for big tech companies, and indeed what’s at stake for India?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.hindustantimes.com/business/uschina-tariff-tussle-gives-india-chance-to-rewire-global-tech-manufacturing-101744606665361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"hindustan_highlight","symbols":["IE0005OL40V9.USD","LU1242518931.SGD","BK4579","LU1582986433.USD","LU0708995401.HKD","LU1868836591.USD","IE000W1ABFV2.USD","LU2125154935.USD","LU2471134879.HKD","LU2750360641.GBP","AAPL","IE00BN29S564.USD","LU0661504455.SGD","LU0109391861.USD","LU1496350502.SGD","LU0170899867.USD","IE00BBT3K403.USD","LU0861579265.USD","LU1066051225.USD","LU1823568750.SGD","SG9999014575.USD","IE00B1BXHZ80.USD","LU0957808578.USD","LU1989772840.SGD","MACW.SI","LU1989772923.USD","LU1116320901.HKD","LU1868837136.USD","LU0456855351.SGD","IE0004445239.USD","LU0345770993.USD","BK4501","HK0000320223.HKD","LU2236285917.USD","LU2458330243.SGD","SG9999001424.SGD","SG9999002232.USD","IE000ITXATA3.USD","ATMP","LU0494093205.USD","LU2247934214.USD","LU2420271590.USD","LU2065169927.USD","LU1066053197.SGD","LU1496350171.SGD","LU1242518857.USD","IE00BZ1G4Q59.USD","LU0417517546.SGD","LU1935042215.USD","LU1261432733.SGD"],"gpt_icon":1},{"id":"2524254742","title":"Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254742","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254742?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee --. -- Initial topline results from two-part, randomized, double-blind, active-controlled study expected late 2026 --. BRISBANE, Calif., April 03, 2025  -- Pacira BioSciences, Inc. , the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201  for the treatment of osteoarthritis, or OA, of the knee. PCRX-201 features an innovative design based on the company’s proprietary high-capacity adenovirus, or HCAd, gene therapy vector platform. It is injected locally into the knee joint to boost cellular production of interleukin-1 receptor antagonist , and block interleukin-1 pathway activation to improve chronic inflammation, pain, and function. PCRX-201’s unique design also features an inducible promoter to mimic t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pacira-biosciences-announces-first-patient-120000005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ATMP","PCRX"],"gpt_icon":0},{"id":"2520361193","title":"Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520361193","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520361193?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:05","pubTimestamp":1742414700,"startTime":"0","endTime":"0","summary":"Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathyBLA granted priorit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/19/3045802/0/en/Capricor-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATMP","BK4139","MDA","CAPR"],"gpt_icon":0},{"id":"2517913794","title":"Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517913794","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517913794?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:02","pubTimestamp":1741176120,"startTime":"0","endTime":"0","summary":"Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three years. Positive 2-year long-term data across multiple mutations of retinitis pigmentosa  from the Phase 1/2 clinical trial of OCU400 demonstrated a durable and statistically significant  improvement in visual function  in all evaluable treated subjects at two years when compared to untreated eyes. The OCU410ST Phase 2/3 clinical trial will randomize 51 subjects, 34 of whom will receive a single, subretinal, 200-μL injection of OCU410ST at a concentration of 1.5 x 1011 vector genomes /mL in the eye with worse visual acuity, and 17 of whom will serve as untreated controls. One-year data will be utilized for the BLA filing planned for 2027. 6-month data from Phase 1 of the OCU410ST GARDian clinical trial demonstrated considerably slower lesion growth (52%) from baseline in treated eyes versus untreated fellow eyes and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-provides-business-fourth-quarter-120200309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAT","BK4201","BK4149","BK4563","LU1974910355.USD","LU0868494617.USD","ATMP","EC","LU0942090050.USD","OCGN","BK4588","LU2106854487.HKD","BK4585","LU0868494708.USD","LU1988902786.USD","IE00BSNM7G36.USD","LU2237438978.USD","BK4139","BK4532","BK4516","BK4597","IE00BD6J9T35.USD","LU2023250504.SGD","LU2264538146.SGD","LU1064131342.USD","BK4568","BK4520","LU1917777945.USD"],"gpt_icon":0},{"id":"2516673201","title":"REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2516673201","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516673201?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:31","pubTimestamp":1741091460,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. today announced the closing of its previously announcedstrategic partnership with Nippon Shinyaku.RGX-121 is on track to be the first gene therapy for MPS II, with potential FDA approval as early as late 2025.ABOUT REGENXBIO Inc.REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atroph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/regenxbio-announces-closing-strategic-partnership-123100596.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regenxbio-announces-closing-strategic-partnership-123100596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4505","BK4563","CNS","ATMP","RGNX","BK4135"],"gpt_icon":0},{"id":"2516112639","title":"Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516112639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516112639?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 03, 2025  -- Ocugen, Inc.  , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s  Committee for Advanced Therapies  for OCU410 and OCU410ST Advanced Therapy Medicinal Product  classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy —an advanced stage of dry age-related macular degeneration —and OCU410ST is being developed for Stargardt disease due to ABCA4-related retinopathies.GA affects 2-3 million people in the United States  and Europe combined. There are two approved therapies in the U.S. that require frequent dosing , however neither therapy has been approved in Europe. Stargardt disease affects 100,000 people in the U.S. and Europe combined, and there are no approved treatments available globally.6-month data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-announces-positive-opinion-ema-140000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","BK4139","IE00B66KJ199.SGD","IE0031619046.USD","BK4532","LU0868494617.USD","BK4585","LU1988902786.USD","ATMP","IE00B19Z4B17.USD","LU0868494708.USD","LU0942090050.USD","LU2237438978.USD","LU1974910355.USD","BK4520","CAT","IE00BD6J9T35.USD","LU2023250504.SGD","LU1064131342.USD","LU1917777945.USD","BK4588","AEIS","LU2106854487.HKD","BK4597","BK4563","IE00BSNM7G36.USD","BK4215","BK4568","MAA","BK4157","IE00B7SZL793.SGD","LU2264538146.SGD","BK4149","OCGN"],"gpt_icon":0},{"id":"2508873114","title":"Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2508873114","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508873114?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:30","pubTimestamp":1738582200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb. 03, 2025  -- Ocugen, Inc.  , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s  Committee for Advanced Therapies  for OCU400 Advanced Therapy Medicinal Product  classification. OCU400 is the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa  indication.“Receiving ATMP classification is another significant milestone toward bringing OCU400 to the market in Europe,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This designation makes it possible to stay on track with our clinical and commercial strategy and potentially provide this novel modifier gene therapy candidate to all RP patients in the United States  and Europe by 2027.”“We are encouraged by the EMA’s recognition of OCU400 as the Phase 3 liMeliGhT clinical trial advances,”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-announces-positive-opinion-european-113000968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4597","LU0868494708.USD","MAA","IE00B19Z4B17.USD","LU2106854487.HKD","IE00B7SZL793.SGD","OCGN","BK4149","BK4139","BK4568","CAT","MDCO","BK4588","LU2237438978.USD","IE00B66KJ199.SGD","LU1064131342.USD","LU1917777945.USD","BK4215","ATMP","LU0868494617.USD","AEIS","BK4516","LU1974910355.USD","BK4532","BK4520","LU0942090050.USD","LU2023250504.SGD","IE00BD6J9T35.USD","BK4157","LU2264538146.SGD","IE0031619046.USD","IE00BSNM7G36.USD","BK4585","LU1988902786.USD"],"gpt_icon":0},{"id":"2503542109","title":"REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2503542109","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503542109?lang=en_us&edition=fundamental","pubTime":"2025-01-14 18:00","pubTimestamp":1736848800,"startTime":"0","endTime":"0","summary":"REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing. REGENXBIO retains rights to RGX-121 Priority Review Voucher  with potential accelerated approval expected in 2025; rolling BLA submission underway. Under the terms of the agreement, REGENXBIO will receive $110 million at closing and up to an additional $700 million if certain milestones are achieved, consisting of $40 million in potential development and regulatory milestones and $660 million in potential sales milestones. REGENXBIO will also receive meaningful double-digit royalties on net sales in the U.S. and Asia .REGENXBIO will lead the manufacturing of both products for clinical and commercial supply in the Licensed Territory. REGENXBIO reserves the right to develo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/regenxbio-nippon-shinyaku-announce-exclusive-100000354.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regenxbio-nippon-shinyaku-announce-exclusive-100000354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATMP","BK4139","BK4563","CNS","BK4135","BK4505","RGNX"],"gpt_icon":0},{"id":"2483180763","title":"Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee","url":"https://stock-news.laohu8.com/highlight/detail?id=2483180763","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483180763?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:05","pubTimestamp":1731596700,"startTime":"0","endTime":"0","summary":"-- Poster to be presented at ACR Convergence annual meeting --PARSIPPANY, N.J., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of inno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981365/0/en/Pacira-Announces-104-Week-Safety-and-Efficacy-Data-Following-Local-Administration-of-PCRX-201-for-Moderate-to-Severe-Osteoarthritis-of-the-Knee.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","ATMP","BK4007"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATMP\",params:#limit:5,,,undefined,":[{"date":"2025-03-03","symbol":"ATMP","amount":0.31838,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"Barclays ETN+ Select MLP ETNs","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-11"},{"date":"2024-11-29","symbol":"ATMP","amount":0.35114,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-29","defaultRemindTime":1732890600000,"name":"Barclays ETN+ Select MLP ETNs","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-09","payableDate":"2024-11-29","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-09"},{"date":"2024-08-28","symbol":"ATMP","amount":0.33437,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-28","defaultRemindTime":1724851800000,"name":"Barclays ETN+ Select MLP ETNs","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-06","payableDate":"2024-08-28","currency":"USD","dateTimestamp":1724817600000,"payDate":"2024-09-06"},{"date":"2024-05-29","symbol":"ATMP","amount":0.33977,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-05-29","defaultRemindTime":1716989400000,"name":"Barclays ETN+ Select MLP ETNs","recordDate":"2024-06-06","payableDate":"2024-05-29","currency":"USD","dateTimestamp":1716955200000,"payDate":"2024-06-06"},{"date":"2024-02-28","symbol":"ATMP","amount":0.30968,"announcedDate":"2024-02-16","type":"dividend","market":"US","newRecordDate":"2024-02-29","defaultRemindTime":1709130600000,"name":"Barclays ETN+ Select MLP ETNs","recordDate":"2024-03-08","payableDate":"2024-02-29","currency":"USD","dateTimestamp":1709096400000,"payDate":"2024-03-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATMP\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-27","recordDate":null,"paymentDate":null,"value":0.2845092,"currency":"USD"},{"executeDate":"2017-05-24","recordDate":null,"paymentDate":null,"value":0.2714382,"currency":"USD"},{"executeDate":"2017-08-24","recordDate":null,"paymentDate":null,"value":0.302208,"currency":"USD"},{"executeDate":"2017-11-28","recordDate":null,"paymentDate":null,"value":0.2959505,"currency":"USD"},{"executeDate":"2018-02-28","recordDate":null,"paymentDate":null,"value":0.2574755,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATMP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6111,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1741233600000}}}